Peptide Research Handbook: Dosing, Half-Lives & Terminology

Peptide research has its own vocabulary — and if you’re new to the field, the terminology can feel like a barrier before you even get to the science. What does “half-life” actually mean for a peptide versus a small molecule drug? Why do research dosages vary so dramatically between studies? How should you interpret “subcutaneous administration at 250 mcg/kg” in a rodent paper? This guide answers those questions directly, building a working reference you can return to whenever a study’s language becomes opaque.

Whether you’re reading preclinical literature for the first time or you’ve been following peptide research for years, having a firm grasp of these foundational concepts helps you evaluate studies more critically, compare compounds more accurately, and understand why translating animal data to human contexts is scientifically complicated. This is a reference guide — built for clarity, not for selling anything.

Research-only notice: This article is educational content about peptide research. Nothing here is medical advice. Peptides discussed are research compounds and not approved for human therapeutic use.

What Exactly Is a Peptide?

A peptide is a short chain of amino acids linked by peptide bonds — the same chemical bonds that connect amino acids in full proteins. The distinction between a peptide and a protein is primarily one of length: by convention, chains of fewer than approximately 50 amino acids are typically called peptides, while longer chains are proteins. In practice, this boundary is fuzzy and context-dependent, with some researchers drawing the line at 30–40 residues.

What makes peptides scientifically interesting is their specificity. Because their three-dimensional structure is determined by their amino acid sequence, peptides can fold into shapes that bind to very particular receptors, enzymes, or binding sites — often mimicking endogenous signaling molecules the body already produces. Compounds like Ghrelin, Kisspeptin, and Neuropeptide Y are all naturally occurring peptides that researchers study because they play significant roles in appetite, hormonal signaling, and neurological function.

Key insight: Peptides are not synonymous with hormones, proteins, or steroids — though there is overlap. Many hormones are peptides (e.g., insulin), but not all peptides are hormones.

Core Research Terminology

Before diving into pharmacokinetics and dosing math, it helps to have a working dictionary. Below are the terms that appear most frequently in peptide literature and what they actually mean in context.

Pharmacokinetics (PK)

Pharmacokinetics describes what the body does to a compound — specifically how it’s absorbed, distributed throughout tissues, metabolized, and eliminated. For peptides, PK data is crucial because most peptides are fragile: they can be degraded by enzymes in the gut or bloodstream before reaching their target receptor. PK studies measure parameters like peak plasma concentration (Cmax), time to peak concentration (Tmax), and area under the curve (AUC), which reflects total exposure over time.

Pharmacodynamics (PD)

Pharmacodynamics describes what the compound does to the body — its biological effects at receptor sites and downstream signaling pathways. In peptide research, PD data might include receptor binding affinity (expressed as Ki or EC50), duration of biological effect, or measurable biomarkers like IGF-1 levels or cytokine concentrations.

EC50 and IC50

The EC50 is the concentration of a compound that produces 50% of its maximum possible effect — a standard measure of potency. A lower EC50 means the compound is more potent (effective at smaller concentrations). The IC50 is the equivalent for inhibitory compounds: the concentration needed to inhibit a process by 50%. These values are often generated in cell culture (in vitro) and don’t always predict in vivo potency accurately.

In Vitro vs. In Vivo vs. In Silico

In vitro research takes place in a controlled lab environment — cell cultures, isolated tissues, test tubes. In vivo research uses living organisms (typically rodents in preclinical studies). In silico research uses computational modeling to predict how a compound will behave. Most peptide compounds progress from in vitro screening → animal in vivo studies → human clinical trials. A compound with impressive in vitro data frequently fails to replicate those results in vivo.

Peptide Analogs and Modifications

A peptide analog is a structurally modified version of a naturally occurring peptide — altered to improve stability, potency, half-life, or receptor selectivity. Common modifications include D-amino acid substitutions (making the peptide resistant to enzymatic cleavage), PEGylation (attaching polyethylene glycol chains to increase size and reduce renal clearance), acetylation, and amidation at the C-terminus. Many research peptides are analogs rather than exact copies of their endogenous counterparts.

Half-Life: What It Means for Peptides

The half-life (t½) of a compound is the time it takes for its plasma concentration to fall by 50%. This is one of the most referenced numbers in pharmacology — and one of the most misunderstood. For peptides specifically, there are two half-life concepts worth distinguishing: the elimination half-life (how long before the compound is cleared from plasma) and the biological half-life (how long the biological effect persists, which can differ substantially).

Most unmodified peptides have short elimination half-lives — often measured in minutes rather than hours. This is because peptidases (enzymes that cleave peptide bonds) are abundant in the bloodstream, liver, kidneys, and gut wall. A short half-life has significant implications for research study design: compounds with t½ values under 30 minutes typically require more frequent administration or continuous infusion to maintain consistent tissue exposure.

Key insight: A short plasma half-life doesn’t necessarily mean short biological effect. Some peptides bind tightly to receptors and trigger downstream signaling that continues long after the peptide itself has been cleared from circulation.

How Modifications Extend Half-Life

Peptide chemists have developed several strategies to extend half-lives. Cyclization — connecting the peptide’s ends to form a ring — reduces enzymatic access and increases metabolic stability. Fatty acid conjugation (the approach used with semaglutide) binds the peptide to albumin in plasma, dramatically extending its circulating half-life. PEGylation increases molecular size, slowing renal filtration. Lanreotide and Octreotide are clinically approved examples where structural modifications transformed short-lived natural peptides into pharmacologically viable drugs.

How Dosing Is Reported in Research Studies

Research dosages are almost always expressed relative to body weight: mcg/kg (micrograms per kilogram) or mg/kg (milligrams per kilogram). This weight-normalized format accounts for the fact that a larger animal requires proportionally more compound to achieve the same tissue concentration. When you read “administered at 1 mg/kg subcutaneously daily,” this means a 250-gram rat received 0.25 mg, while a 500-gram rat in the same study received 0.5 mg.

Understanding this becomes especially important when researchers attempt to contextualize animal study findings. The raw mg/kg number from a mouse study cannot simply be multiplied by a human body weight to estimate a relevant human dose — this is one of the most common and consequential mistakes in lay interpretations of peptide research.

Common Units in Peptide Literature

mcg (microgram) — one millionth of a gram; common for highly potent peptides
mg (milligram) — one thousandth of a gram; used for less potent or higher-volume compounds
nmol/kg — nanomoles per kilogram; molar dosing notation used when comparing molecular weight differences between compounds
IU (International Unit) — a biological activity-based unit, used for some peptide hormones; not interchangeable with weight-based units without a conversion factor

Routes of Administration

How a peptide is delivered dramatically affects its pharmacokinetics. The route determines absorption speed, bioavailability, and which tissues the compound reaches first. In research literature, you’ll encounter several standard administration routes.

Subcutaneous (SC)

Injection into the subcutaneous fat layer beneath the skin. This is the most common route in peptide research because it allows slow, sustained absorption into systemic circulation. Bioavailability for SC peptide administration is often in the 60–90% range, making it predictable and consistent for research purposes.

Intravenous (IV)

Direct delivery into a vein produces 100% bioavailability by definition — the compound bypasses all absorption steps. IV administration is common in PK studies where researchers need precise control over plasma concentration curves. It typically produces a sharper Cmax and faster clearance compared to SC dosing.

Intramuscular (IM)

Injection into muscle tissue. Absorption is generally faster than SC but slower than IV. Some depot formulations are designed for IM use, where the compound slowly diffuses from the muscle over days or weeks.

Intranasal

Delivery through the nasal mucosa. Relevant for neurologically targeted peptides — the nasal route offers proximity to the olfactory bulb and potential direct access to brain tissue, bypassing the blood-brain barrier to some degree. PACAP-38 and related neuropeptides are sometimes studied via this route.

Oral

Most unmodified peptides are poorly suited to oral delivery because digestive enzymes and stomach acid degrade them before they can be absorbed. Oral peptide delivery is an active research area, but most research compounds are not orally bioavailable without significant formulation engineering. Linaclotide is a notable exception — it’s designed specifically to act locally in the gut without systemic absorption.

Allometric Scaling: Why Animal Doses Don’t Translate Directly

One of the most important concepts for anyone reading preclinical peptide research is allometric scaling — the mathematical relationship between body size and physiological parameters like metabolic rate, organ blood flow, and drug clearance. Smaller animals have faster metabolisms relative to their body weight, which means they typically clear compounds faster and may require proportionally higher doses to achieve equivalent plasma exposure.

The FDA uses a standardized conversion method based on body surface area (BSA) rather than simple weight to extrapolate from animal models to humans. The conversion factor between species varies considerably: the mouse-to-human conversion factor is approximately 12.3, meaning a dose of 10 mg/kg in a mouse is roughly equivalent to a human dose of approximately 0.8 mg/kg by BSA scaling — not 10 mg/kg as a naive calculation might suggest.

Caution: Allometric scaling provides an estimate for study design purposes — it is not a formula for determining human doses. Differences in receptor density, protein binding, and metabolic pathways mean animal-to-human extrapolation is imprecise even under ideal conditions.

Stability, Degradation, and Storage

Peptides are chemically labile — more susceptible to degradation than most small molecule drugs. The primary threats are enzymatic cleavage, oxidation, hydrolysis, and aggregation. Understanding these mechanisms matters for interpreting research data, particularly when comparing studies that used different storage or preparation conditions.

In lyophilized (freeze-dried) form, most peptides are stable at low temperatures for extended periods. Once reconstituted in solution, stability decreases significantly — particularly at room temperature. Factors that accelerate degradation include light exposure, repeated freeze-thaw cycles, and pH extremes. Research protocols typically specify storage conditions carefully because variability here can produce inconsistent biological results across experiments. If you need a practical reference for reconstitution best practices, the PeptideBible reconstitution guide covers this in detail.

How to Read a Peptide Research Paper

When you encounter a new peptide study, a structured approach helps you extract signal from noise. The methods section is where the most operationally important information lives — not the abstract. Look for: the animal model used, the exact dose and unit expression, the route of administration, the dosing frequency, and the duration of the experiment. These parameters collectively determine how much weight the findings should carry.

Pay attention to the outcome measures. Are they surrogate markers (e.g., a biomarker like IGF-1 levels) or functional endpoints (e.g., tissue repair measured histologically)? Surrogate markers are valuable but can be misleading if they don’t correlate with meaningful biological outcomes. Also note the sample size — many peptide studies use n=5 to n=10 animals per group, which is sufficient for initial exploration but not for drawing strong conclusions. Replication across independent labs is a much stronger signal than a single well-designed study.

Key insight: The abstract summarizes what the authors want you to take away. The methods section tells you whether the study actually supports that conclusion. Always read the methods.

Frequently Asked Questions

What’s the difference between a peptide and a protein?

Both are chains of amino acids linked by peptide bonds. The distinction is largely one of length: chains under approximately 50 amino acids are typically called peptides, while longer chains are proteins. The boundary is not rigidly defined and varies by convention in different research contexts.

Why do most peptides have short half-lives?

Peptidases — enzymes that cleave peptide bonds — are abundant in blood plasma, the liver, kidneys, and gastrointestinal tract. Unmodified peptides are rapidly recognized and broken down by these enzymes. Structural modifications like cyclization, D-amino acid substitution, or PEGylation can substantially extend a peptide’s half-life by reducing enzymatic recognition.

Why can’t I just multiply an animal dose by my body weight to estimate a human dose?

Because metabolic rate, drug clearance, receptor density, and organ function scale differently across species. A mouse metabolizes compounds roughly 12 times faster per kilogram than a human. Body surface area (BSA) scaling provides a better — though still imperfect — cross-species estimate. The FDA uses BSA-based conversion factors specifically because direct weight-based extrapolation consistently overestimates appropriate human doses.

What does “mcg/kg” mean in a research study?

Micrograms per kilogram of body weight. It’s a weight-normalized dosing unit that accounts for differences in animal size within a study. If a study uses 250 mcg/kg in rats, a 300-gram rat received 75 mcg total, while a 400-gram rat received 100 mcg total — even though they were in the same dosing group.

What is bioavailability and why does it matter?

Bioavailability refers to the fraction of an administered dose that reaches systemic circulation in active form. Intravenous delivery has 100% bioavailability by definition. Subcutaneous administration of peptides typically achieves 60–90% bioavailability. Oral delivery of most unmodified peptides has near-zero bioavailability due to digestive degradation. Bioavailability directly affects how study doses should be interpreted across different administration routes.

What’s the difference between EC50 and IC50?

EC50 is the concentration that produces 50% of a compound’s maximum stimulatory effect — lower EC50 means higher potency. IC50 is the concentration that inhibits a process by 50% — used for antagonists or enzyme inhibitors. Both are standard measures of potency generated in laboratory assays, usually in cell cultures.

How should lyophilized peptides be stored?

Lyophilized (freeze-dried) peptides should generally be stored at -20°C or colder, away from light and moisture. Once reconstituted into solution, they are less stable and should typically be refrigerated at 4°C, used within a few weeks, and protected from repeated freeze-thaw cycles. Specific storage requirements vary by compound. See the PeptideBible storage guide for more detailed guidance.

Are all research peptides synthetic?

Most research peptides are synthetically produced, even when they are identical in sequence to naturally occurring peptides. Solid-phase peptide synthesis (SPPS) is the dominant manufacturing method, allowing precise construction of the amino acid sequence. Synthetic production enables consistent purity, scalability, and the ability to introduce non-natural modifications that a biological expression system couldn’t produce.

Researchers often source compounds from SourcePeptides — they provide third-party purity testing (COAs) and fast US shipping.